These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 21966491)

  • 1. Engagement of overexpressed Her2 with GEP100 induces autonomous invasive activities and provides a biomarker for metastases of lung adenocarcinoma.
    Menju T; Hashimoto S; Hashimoto A; Otsuka Y; Handa H; Ogawa E; Toda Y; Wada H; Date H; Sabe H
    PLoS One; 2011; 6(9):e25301. PubMed ID: 21966491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GEP100 links epidermal growth factor receptor signalling to Arf6 activation to induce breast cancer invasion.
    Morishige M; Hashimoto S; Ogawa E; Toda Y; Kotani H; Hirose M; Wei S; Hashimoto A; Yamada A; Yano H; Mazaki Y; Kodama H; Nio Y; Manabe T; Wada H; Kobayashi H; Sabe H
    Nat Cell Biol; 2008 Jan; 10(1):85-92. PubMed ID: 18084281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidermal growth factor receptor-GEP100-Arf6 axis affects the prognosis of lung adenocarcinoma.
    Oka S; Uramoto H; Shimokawa H; Yamada S; Tanaka F
    Oncology; 2014; 86(5-6):263-70. PubMed ID: 24902879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequent overexpression of AMAP1, an Arf6 effector in cell invasion, is characteristic of the MMTV-PyMT rather than the MMTV-Neu human breast cancer model.
    Otsuka Y; Oikawa T; Yoshino H; Hashimoto S; Handa H; Yamamoto H; Hashimoto A; Sabe H
    Cell Commun Signal; 2018 Jan; 16(1):1. PubMed ID: 29329590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GEP100-Arf6-AMAP1-cortactin pathway frequently used in cancer invasion is activated by VEGFR2 to promote angiogenesis.
    Hashimoto A; Hashimoto S; Ando R; Noda K; Ogawa E; Kotani H; Hirose M; Menju T; Morishige M; Manabe T; Toda Y; Ishida S; Sabe H
    PLoS One; 2011; 6(8):e23359. PubMed ID: 21858086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GEP100/Arf6 is required for epidermal growth factor-induced ERK/Rac1 signaling and cell migration in human hepatoma HepG2 cells.
    Hu Z; Du J; Yang L; Zhu Y; Yang Y; Zheng D; Someya A; Gu L; Lu X
    PLoS One; 2012; 7(6):e38777. PubMed ID: 22701712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The EGFR-GEP100-Arf6-AMAP1 signaling pathway specific to breast cancer invasion and metastasis.
    Sabe H; Hashimoto S; Morishige M; Ogawa E; Hashimoto A; Nam JM; Miura K; Yano H; Onodera Y
    Traffic; 2009 Aug; 10(8):982-93. PubMed ID: 19416474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The EGFR-GEP100-Arf6 pathway in breast cancer: Full invasiveness is not from the inside.
    Sabe H; Hashimoto S; Morishige M; Hashimoto A; Ogawa E
    Cell Adh Migr; 2008; 2(2):71-3. PubMed ID: 19262097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GEP100 regulates epidermal growth factor-induced MDA-MB-231 breast cancer cell invasion through the activation of Arf6/ERK/uPAR signaling pathway.
    Hu Z; Xu R; Liu J; Zhang Y; Du J; Li W; Zhang W; Li Y; Zhu Y; Gu L
    Exp Cell Res; 2013 Aug; 319(13):1932-1941. PubMed ID: 23747719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phosphatidylinositol-4-phosphate 5-kinase and GEP100/Brag2 protein mediate antiangiogenic signaling by semaphorin 3E-plexin-D1 through Arf6 protein.
    Sakurai A; Jian X; Lee CJ; Manavski Y; Chavakis E; Donaldson J; Randazzo PA; Gutkind JS
    J Biol Chem; 2011 Sep; 286(39):34335-45. PubMed ID: 21795701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HER2 status in lung adenocarcinoma: a comparison of immunohistochemistry, fluorescence in situ hybridization (FISH), dual-ISH, and gene mutations.
    Yoshizawa A; Sumiyoshi S; Sonobe M; Kobayashi M; Uehara T; Fujimoto M; Tsuruyama T; Date H; Haga H
    Lung Cancer; 2014 Sep; 85(3):373-8. PubMed ID: 25047676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation.
    Takezawa K; Pirazzoli V; Arcila ME; Nebhan CA; Song X; de Stanchina E; Ohashi K; Janjigian YY; Spitzler PJ; Melnick MA; Riely GJ; Kris MG; Miller VA; Ladanyi M; Politi K; Pao W
    Cancer Discov; 2012 Oct; 2(10):922-33. PubMed ID: 22956644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lung adenocarcinomas with HER2-activating mutations are associated with distinct clinical features and HER2/EGFR copy number gains.
    Li C; Sun Y; Fang R; Han X; Luo X; Wang R; Pan Y; Hu H; Zhang Y; Pao W; Shen L; Ji H; Chen H
    J Thorac Oncol; 2012 Jan; 7(1):85-9. PubMed ID: 22071781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Arf6 GEF GEP100/BRAG2 regulates cell adhesion by controlling endocytosis of beta1 integrins.
    Dunphy JL; Moravec R; Ly K; Lasell TK; Melancon P; Casanova JE
    Curr Biol; 2006 Feb; 16(3):315-20. PubMed ID: 16461286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p140Cap suppresses the invasive properties of highly metastatic MTLn3-EGFR cells via impaired cortactin phosphorylation.
    Damiano L; Le Dévédec SE; Di Stefano P; Repetto D; Lalai R; Truong H; Xiong JL; Danen EH; Yan K; Verbeek FJ; De Luca E; Attanasio F; Buccione R; Turco E; van de Water B; Defilippi P
    Oncogene; 2012 Feb; 31(5):624-33. PubMed ID: 21725361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Down-regulation of GEP100 causes increase in E-cadherin levels and inhibits pancreatic cancer cell invasion.
    Xie CG; Wei SM; Chen JM; Xu XF; Cai JT; Chen QY; Jia LT
    PLoS One; 2012; 7(5):e37854. PubMed ID: 22662237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lung Adenocarcinoma With MUC4 Expression Is Associated With Smoking Status, HER2 Protein Expression, and Poor Prognosis: Clinicopathologic Analysis of 338 Cases.
    Rokutan-Kurata M; Yoshizawa A; Sumiyoshi S; Sonobe M; Menju T; Momose M; Koyama M; Shigeto S; Fujimoto M; Zhang M; Morita S; Date H; Haga H
    Clin Lung Cancer; 2017 Jul; 18(4):e273-e281. PubMed ID: 28065467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatocyte growth factor and HER2/neu downregulate expression of apoptosis-inducing factor in non-small cell lung cancer.
    Chiang YY; Chow KC; Lin TY; Chiang IP; Fang HY
    Oncol Rep; 2014 Feb; 31(2):597-604. PubMed ID: 24276579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer.
    Onn A; Correa AM; Gilcrease M; Isobe T; Massarelli E; Bucana CD; O'Reilly MS; Hong WK; Fidler IJ; Putnam JB; Herbst RS
    Clin Cancer Res; 2004 Jan; 10(1 Pt 1):136-43. PubMed ID: 14734462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene amplification and protein expression of EGFR and HER2 by chromogenic in situ hybridisation and immunohistochemistry in atypical adenomatous hyperplasia and adenocarcinoma of the lung.
    Awaya H; Takeshima Y; Furonaka O; Kohno N; Inai K
    J Clin Pathol; 2005 Oct; 58(10):1076-80. PubMed ID: 16189154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.